Human endogenous retrovirus (HERV) sequences comprise 8% of the total human genome DNA, and they entered the genome between 10 and 50 million years ago
HERVs are unique tumor targets that are overexpressed in more than 80% of solid tumors, but not in normal tissues
SunnyBay Biotech has developed therapeutics targeting the HERV-K supergroup of HERVs
Our approach for moving novel HERV-K therapeutic antibody-drug conjugates (ADCs), which reduce tumor growth, inhibit metastasis, and prolong survival in murine models of breast and lung cancers, from the lab into the clinic will be discussed
